The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD:Results of the MINOXIS study

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 52-59

  Schneider, Andreas ^a   Drechsler, Christiane ^a   Krane, Vera ^a   Krieter, Detlef H ^a   Scharnagl, Hubert ^b   Schneider, Markus P ^c   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; MYELOPEROXIDASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS MEMBRANE; FEMALE; FERRITIN BLOOD LEVEL; FLOW RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION INFLAMMATION SCORE; MULTICENTER STUDY; NEPHRITIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL;

AGED; C-REACTIVE PROTEIN; CHRONIC DISEASE; ENDPOINT DETERMINATION; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84857071080     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02710311     Document Type: Article

References (27)

1. Voormolen N, Grootendorst DC, Urlings TA, Boeschoten EW, Sijpkens YW, Huisman RM, Krediet RT, Dekker FW: Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron Clin Pract 115: c133-c141, 2010
2. Auer J, Oliver DO, Winearls CG: The quality of life of dialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol Suppl 131: 61-65, 1990
3. Delano BG: Improvements in quality of life following treatment with rHuEPO in anemic hemodialysis patients. Am J Kidney Dis 14[Suppl 1]: 14-18, 1989
4. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: 1908-1914, 2003
5. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: A 15 year single center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl S6-S11, 2003
6. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
7. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
8. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989
9. Ayli D, Ayli M, Azak A, Yüksel C, Kosmaz GP, Atilgan G, Dede F, Abayli E, Camlibel M: The effect of high flux hemodialysis on renal anemia. J Nephrol 17: 701-706, 2004
10. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C: Results from EuCliD (European Clinical Dialysis Database): Impact of shifting treatment modality. Int J Artif Organs 25: 1049-1060, 2002
11. Yokoyama H, Kawaguchi T, Wada T, Takahashi Y, Higashi T, Yamazaki S, Fukuhara S, Akiba T, Akizawa T, Asano Y, Kurokawa K, Saito A J-DOPPS Research Group: Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in Japanese patients on chronic non reuse hemodialysis:Aprospective cohort study from the JDOPPSIIstudy. Nephron Clin Pract 109: c100-c108, 2008
12. Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, Farina M, La Milia V, Grassi C, Borghi M, Redaelli B, Conte F, Ratto G, Cabiddu G, Grossi C, Modenese R: Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 15: 1399-1409, 2000
13. Opatrný K, Reischig T, Vienken J, Eiselt J, Vít L, Opatrná S, Sefrna F, Racek J, Brown GS: Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 26: 181-188, 2002
14. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773, 2003
15. Bárány P, Divino Filho JC, Bergström J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodi-alysis patients. Am J Kidney Dis 29: 565-568, 1997
16. Hoffmann U, Fischereder M, Marx M, Schweda F, Lang B, Straub RH, Krämer BK: Induction of cytokines and adhesion molecules in stable hemodialysis patients: Is there an effect of membrane material? Am J Nephrol 23: 442-447, 2003
17. Stenvinkel P: Anaemia and inflammation: What are the implications for the nephrologist? Nephrol Dial Transplant 18 [Suppl 8]: viii17-22, 2003
18. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 18: 1272-1280, 2003
19. Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, De Simone W, Mandalari A, Brunori G, Amato M, Cianciaruso B, Zoccali C: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 21: 991-998, 2006
20. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: A malnutrition-inflammation score is correlated with morbidity and mortalityin maintenance hemodialysispatients.Am J Kidney Dis 38: 1251-1263, 2001
21. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R Anaemia Working Group of European Renal Best Practice (ERBP): Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 25: 2846-2850, 2010
22. Kovesdy CP, Kalantar-Zadeh K: Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Ne-phrology (Carlton) 14: 408-415, 2009
23. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 17[Suppl 8]: 29-32, discussion 39-40, 2002
24. Kalantar-Zadeh K, Brennan ML, Hazen SL: Serum myeloperox-idase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 48: 59-68, 2006
25. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodial-ysis patients. J Am Soc Nephrol 20: 645-654, 2009
26. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemo dialysis. N Engl J Med 347: 2010-2019, 2002
27. Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD: Effects of low and high flux dialyzers on oxidative stress and insulin resistance. Blood Purif 26: 213-220, 2008